OXiGENE公司公布Combretastatin结合紫杉醇和卡铂治疗的阶段成果

(BW)(MA-OXIGENE)(OXGN)(OXGN.ST) OXiGENE公司公布对晚期成像恶性肿瘤患者进行Combretastatin (CA4P)结合紫杉醇和卡铂治疗的第二阶段研究成果

美国商业资讯2006年12月27日马萨诸塞州沃尔瑟姆消息——OXiGENE公司（纳斯达克股票代码：OXGN，斯德哥尔摩证券交易所：OXGN）今天宣布，完成了对晚期成像恶性肿瘤患者的第二阶段研究。这是一项随机的开放标记研究，共对13名患者在进行45或63mg/m(2)的CA4P静脉给药后，使用紫杉醇结合卡铂治疗的情况进行了研究。这项试验研究的目的是确定使用CA4P阻止血液流动的最佳剂量，证明CA4P结合紫杉醇和卡铂治疗的安全性及有效性。除一名患者由于临床反应良好，仍在继续进行可选择的延期试验外，其余患者的试验数据已被收集并加以分析。

这项研究的整体数据表明达到了研究目标。所成图像证实阻止了大多数种类的晚期成像恶性肿瘤的血液流动，安全性符合预期，多名患者表现出产生肿瘤反应。OXiGENE公司总裁兼首席执行官、医学博士Richard Chin说：“我们对这项研究结果感到非常高兴，完成这项研究再次表明我们致力于及时实施我们的项目。”

这项研究是由Wallace Akerley博士及其合作研究者在犹他州立大学杭兹曼癌症中心（HCI）进行的。预计，这些研究成果将提交给即将举行的2007年科学大会。

背景材料　

尽管放射疗法、化学疗法以及外科手术在治疗肿瘤方面取得了进步，但是仍然需要一些新的作用机理疗法来满足医疗需求，这些新的作用机理疗法可能会与化学疗法及放射疗法在治疗效果上相互促进。肿瘤血管已经成为开发新的肿瘤疗法相对较新的一个标靶，重点主要放在研究可阻止新血管形成和生长的化合物上（即抗血管新生疗法）。CA4P是一种新型抗肿瘤药物，在迄今为止的临床研究中已经显现出针对肿瘤血管的有效性及选择毒性。我们优化CA4P抗肿瘤活性的策略就是要把它与细胞毒性剂结合使用。把CA4P与其他细胞毒性剂结合使用的基本原理是，不同种类具有潜在良好作用机理以及具有非重叠毒性特征的药物同时使用可能会达到协同抗肿瘤效果。在动物研究中，CA4P已经显现出可以提高好几种化学疗法药物及放射疗法的抗肿瘤效果。

关于OXiGENE公司

OXiGENE公司是新兴的制药公司，开发治疗肿瘤和眼疾的新型小分子疗法。公司主要致力于备选药物的临床改进，这些药物可选择性地干扰与实体瘤增长和导致视觉缺陷相关的异常血管。OXiGENE公司致力于利用其拥有的知识产权及开发疗法的专门技术来挽救病人生命，提高病人用药效果。

免责声明

本新闻稿包含1995年《私人证券诉讼改革法案》界定的“前瞻性声明”。本新闻稿中的一些或所有前瞻性声明可能是错误的。前瞻性声明会受到OXiGENE公司可能进行的错误设想或受到已知或未知风险和不确定性因素的影响。有关可能导致实际结果与这些前瞻性声明所述的结果产生重大差异的因素的其他信息包含在OXiGENE公司提交给美国证券交易委员会的报告中，其中包括OXiGENE公司的10-Q表格、8-K和10-K报告。不过，无论是由于出现新信息、未来事件，还是由于出现其他情况，OXiGENE公司均不承担公开更新这些前瞻性声明的义务。请参考我们有关截至2005年12月31日为止财年的10-K表格年度报告，了解对这些风险的描述。

联系方式：OXiGENE公司　　　　　投资者关系部 781-547-5900

(BW)(MA-OXIGENE)(OXGN)(OXGN.ST) OXiGENE Announces Positive Results of Phase II Study of Combretastatin (CA4P) in Combination with Paclitaxel and Carboplatin in Patients with Advanced Imageable Malignancies

WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 27, 2006--

OXiGENE, Inc.(NASDAQ: OXGN, XSSE: OXGN) today announced it has completed a Phase II Study in patients with advanced imageable malignancies. This was a randomized open-label study of intravenous CA4P administered at 45 or 63 mg/m(2) followed by paclitaxel and carboplatin in 13 patients. The objectives of the trial were to identify optimal dose of CA4P for blood flow shutdown and to demonstrate safety and efficacy of CA4P in combination with paclitaxel and carboplatin. All patient data have been collected and analyzed, with the exception of one patient who is still continuing in the optional extension phase of the protocol due to continued good clinical response.

Topline data from the study indicate that the objectives of the study were met. The imaging confirmed blood flow shutdown in a wide variety of advanced imageable malignancies, safety is in line with expectations and tumor responses were seen in multiple patients. "We are pleased with the study results, and the completion of this study again illustrates our focus on timely execution of our programs" said OXiGENE's President and CEO, Richard Chin, MD.

The study was conducted at the Huntsman Cancer Center (HCI), University of Utah by Dr. Wallace Akerley and his co-investigators. It is anticipated that the results will be presented at an upcoming scientific meeting in 2007.

Background

Despite advances in the management of cancer with radiotherapy, chemotherapy and surgery, there is an unmet medical need for treatments with new mechanisms of action, which may act synergistically with chemotherapy and radiotherapy. Tumor vasculature has become a relatively recent target in the development of new cancer therapies, with the focus aimed primarily on compounds that prevent the formation and growth of new blood vessels (i.e., anti-angiogenesis therapy). Combretastatin A-4 Phosphate (CA4P) is a novel anti-cancer agent that has displayed potent and selective toxicity towards tumor vasculature in clinical studies to date. Our strategy for optimizing the antitumor activity of CA4P is to combine it with cytotoxic agents. The rationale for combining CA4P with other cytotoxic regimens stems from the hypothesis that agents with different and potentially complimentary mechanisms of action and with a non-overlapping toxicity profile may achieve synergistic antitumor activity when administered concurrently. CA4P has been shown to enhance and the anti-tumor effects of several chemotherapeutic agents and radiation in animal studies.

About OXiGENE, Inc.

OXiGENE is an emerging pharmaceutical company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients.

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's Form 10-Q, 8-K and 10-K reports. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2005 for a description of these risks.

CONTACT: OXiGENE, Inc. Investor Relations 781-547-5900